Weekly paclitaxel in the management of ovarian cancer.
The weekly administration of paclitaxel has the potential to increase the effectiveness of this cycle-specific agent against slowly growing solid tumors. Clinical evaluation has confirmed that paclitaxel can be safely delivered on a weekly schedule as a 1-hour infusion, with objective responses being observed in platinum-resistant ovarian cancer. Limited data suggest that the schedule may also possess activity against tumors previously demonstrated to be resistant to paclitaxel-containing regimens delivered on an every-3-week schedule. Ongoing trials in ovarian cancer are examining the clinical utility of this approach as a second-line treatment option in carefully defined paclitaxel-resistant disease and as a consolidation strategy in high-risk, early stage disease following initial therapy with a carboplatin/paclitaxel combination regimen.
Markman
M
M
The Cleveland Clinic Taussig Cancer Center and the Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel